This Week in Biotech: Gilead Sciences, Inc. (GILD), GlaxoSmithKline plc (ADR) (GSK)

Page 1 of 2

With the SPDR S&P Biotech Index up 31% over the trailing-12-month period, it’s evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let’s have a look at some of the rulings, studies, and companies that made waves in the sector last week.

For a second week in a row we were privy to a little bit of everything: FDA panel reviews, new clinical data, detailed FDA updates, buyout rumors, and even snowstorms.

On Monday, Depomed Inc (NASDAQ:DEPO) announced that the Reproductive Health Drugs Advisory Committee was recommending against the approval of its hot-flash drug, Sefelsa, with 12 of 14 members ushering in a thumbs-down. The negative ruling wasn’t a huge shock, as Sefelsa didn’t meet its primary endpoints in the first two clinical trials and had what I deem an abnormally large number of patients drop out of all three trials. In the meantime, DepoMed plans to completely abandon all spending and research on Sefelsa unless it appears the drug has a good shot at gaining approval. Shares dipped by 9.5% this week.

Gilead Sciences, Inc. (NASDAQ:GILD)Gilead Sciences, Inc. (NASDAQ:GILD) continues to churn out nothing but fantastic news with its experimental oral hepatitis-C drug, Sofosbuvir. In a mid-stage combination trial with Johnson & Johnson (NYSE:JNJ) and Medivir‘s Simeprevir, the combo cleared all detectable levels of the virus in 100% of genotype 1 patients — the most common form of hepatitis-C. With no adverse events reported, Sofosbuvir once again proved to the biotech community that it could be the standalone and combination drug of choice in oral hepatitis-C care.

Pharmaceutical company Impax Laboratories Inc (NASDAQ:IPXL) was crushed on Tuesday, after it provided an update to investors regarding the FDA’s complete response letter on idiopathic Parkinson’s disease drug Rytary. According to the update, the FDA cited 12 points of concern with its Hayward, Calif., facility, of which three were repeat violations from a warning letter sent to the company in 2011. What this means for Impax is longer delays in attempting to rectify these problems and probably another nine months to a year before Rytary goes before the FDA for a third time. Shares fell nearly 17% on the week.

Page 1 of 2
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 10 Most Expensive iPhone Apps

The 9 Most Expensive Designer Shoes in the World

The 10 Most Expensive Cigarette Brands

The 10 Most Expensive Law Schools in the US

The 10 Best Wall Street Movies

The 10 Most Expensive Golf Clubs Ever Sold

The 10 Most Expensive Golf Memberships

The 10 Best Disney Characters Ever Created

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

The 10 Most Peaceful Countries in the World

5 Big Reasons Communism Failed

The 15 Most Famous Carl Icahn Quotes

10 Scary Animals that are Actually Harmless

The 8 Most Famous Singer-Actors in Entertainment

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!